Cargando…
Atorvastatin Augments Gemcitabine-Mediated Anti-Cancer Effects by Inhibiting Yes-Associated Protein in Human Cholangiocarcinoma Cells
Cholangiocarcinoma (CCA) is associated with high mortality rates because of its resistance to conventional gemcitabine-based chemotherapy. Hydroxy-methyl-glutaryl-coenzyme A reductase inhibitors (statins) reportedly exert anti-cancer effects in CCA and lower the risk of CCA; however, the underlying...
Autores principales: | Kitagawa, Koh, Moriya, Kei, Kaji, Kosuke, Saikawa, Soichiro, Sato, Shinya, Nishimura, Norihisa, Namisaki, Tadashi, Akahane, Takemi, Mitoro, Akira, Yoshiji, Hitoshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7589854/ https://www.ncbi.nlm.nih.gov/pubmed/33066548 http://dx.doi.org/10.3390/ijms21207588 |
Ejemplares similares
-
Sulforaphane Potentiates Gemcitabine-Mediated Anti-Cancer Effects against Intrahepatic Cholangiocarcinoma by Inhibiting HDAC Activity
por: Tomooka, Fumimasa, et al.
Publicado: (2023) -
Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity
por: Kaji, Kosuke, et al.
Publicado: (2017) -
Comparison of serum fibrosis biomarkers for diagnosing significant liver fibrosis in patients with chronic hepatitis B
por: Tsuji, Yuki, et al.
Publicado: (2020) -
Effect of L-carnitine on health-related quality of life in patients with liver cirrhosis
por: Sato, Shinya, et al.
Publicado: (2020) -
Bi-monthly hepatic arterial infusion chemotherapy as a novel strategy for advanced hepatocellular carcinoma in decompensated cirrhotic patients
por: Moriya, Kei, et al.
Publicado: (2019)